Anixa Biosciences and MolGenie announced early potency analysis of SARS-CoV-2 protease inhibitor
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound…
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound…
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
On Jan. 20, 2022, Gilead Sciences announced that the U.S. Food and Drug Administration had granted expedited approval…
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…
On Jan. 18, 2022, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
On Jan. 16, 2022, the WHO announced that it had shipped 1.1 million COVID-19 vaccines to Rwanda on…
On Jan. 14, 2022, the WHO announced that it had recommended two new drugs for COVID-19, providing yet…
On Jan. 13, 2022, OraSure Technologies that its InteliSwabï¾® COVID-19 rapid tests detected the Omicron variant as effectively…
On Jan. 14, 2022, the U.S. Department of Defense, in coordination with the U.S. Department of Health and…
On Jan. 12, 2022, Novavax and SK bioscience, a vaccine business subsidiary of Korea-based SK Group, announced that…
On Jan. 12, 2022, Pfizer announced positive top-line results from a Phase 3 study describing the safety and…
On Jan. 11, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration had expanded the…
On Jan. 11, 2022, GlaxoSmithKline and Vir Biotechnology announced the US Government had purchased an additional 600,000 doses…
On Jan. 10, 2022, Novartis Molecular Partners announced that Part A of the EMPATHY clinical trial that compared…
On Jan. 10, 2022, Novavax and Serum Institute of India announced a regulatory submission to the South African…
On Jan. 10, 2022, the Biden-Harris Administration announced it was requiring insurance companies and group health plans to…
On Jan. 7, 2022, the Department of Defense, in coordination with the U.S. Department of Health and Human…
On Jan. 5, 2021, Humanigen announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study had been achieved….
On Jan. 5, 2022, Pfizer and BioNTech announced a new research, development and commercialization collaboration to develop a…
On Jan 5, 2022, NRx Pharmaceuticals announced that it had submitted an application for Emergency Use Authorization (EUA)…
On Jan. 4, 2022, Pfizer announced that the U.S. government had committed to purchasing an additional 10 million…
On Jan. 4, 2022, Tonix Pharmaceuticals announced an exclusive option agreement and research collaboration with Kansas State University…
On Jan. 3, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration had expanded the…
On Jan. 3, 2022, Amyris and ImmunityBio announced the completion of a previously announced joint venture agreement to…
On Jan. 3, 2021, Humanigen announced that a manuscript detailing the results of an analysis of CRP levels…
On Dec. 30, 2021, Johnson & Johnson announced preliminary results from the South African Phase 3b Sisonke study…
On Dec. 29, 2021, NRx Pharmaceuticals announced that it hds filed a new Breakthrough Therapy Designation (BTD) request…
On Dec. 29, 2021, the Department of Defense (DoD), on behalf of and in coordination with the U.S….
On Dec. 28, 2021, Novavax and Serum Institute of India announced that the Drugs Controller General of India…